Gladstone Institutional Advisory’s Aurinia Pharmaceuticals AUPH Stock Holding History

Gladstone Institutional Advisory’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-17,300	Closed	-$190K	–	640
2023 Q1	$190K	Sell	17,300 -2,500	-13%	-$22K	0.01%	616
2022 Q4	$85.5K	Sell	19,800 -33,300	-63%	-$193K	0.01%	621
2022 Q3	$399K	Sell	53,100 -19,300	-27%	-$167K	0.03%	434
2022 Q2	$728K	Sell	72,400 -7,000	-9%	-$78.3K	0.06%	336
2022 Q1	$983K	Sell	79,400 -23,200	-23%	-$359K	0.07%	295
2021 Q4	$2.35M	Buy	102,600 +26,100	+34%	+$618K	0.18%	154
2021 Q3	$1.69M	Sell	76,500 -12,800	-14%	-$203K	0.17%	162
2021 Q2	$1.16M	Hold	89,300	–	–	0.14%	175
2021 Q1	$1.16M	Sell	89,300 -2,450	-3%	-$35.5K	0.18%	126
2020 Q4	$1.27M	Buy	91,750 +19,000	+26%	+$277K	0.25%	88
2020 Q3	$1.07M	Buy	72,750 +10,850	+18%	+$157K	0.26%	90
2020 Q2	$1.01M	Buy	61,900 +6,998	+13%	+$112K	0.26%	83
2020 Q1	$797K	Buy	+54,902	New	+$968K	0.21%	102

Other funds holding AUPH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Gladstone Institutional Advisory's AUPH Position: Q2 2023 in Review

Gladstone Institutional Advisory sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2023, closing a stake of 17,300 shares — an estimated $190K sold.

Gladstone Institutional Advisory first reported a position in AUPH in Q1 2020 and held it in 13 quarters. The position peaked at $2.35M in Q4 2021. 200 funds tracked by Wall St. Rank hold AUPH as of Q2 2023.

Gladstone Institutional Advisory reported no remaining Aurinia Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Gladstone Institutional Advisory sold 17,300 Aurinia Pharmaceuticals shares in Q2 2023, an estimated $190K.
Gladstone Institutional Advisory first reported a position in Aurinia Pharmaceuticals in Q1 2020 and held it in 13 quarters.
Gladstone Institutional Advisory's Aurinia Pharmaceuticals position peaked at $2.35M in Q4 2021.
200 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2023.

Based on Gladstone Institutional Advisory's 13F filing for Q2 2023, filed 10 Aug 2023.